Semaglutide, the active ingredient in Ozempic and Wegovy, extended lifespan in old female mice in a new Nature study from UC Berkeley. Treatment began at 20 months of age and mimicked many benefits of calorie restriction. In a direct comparison, the drug also showed more favourable trajectories than matched calorie restriction in exploratory drive, spatial memory and glucose control. But this is mouse research in females only, with no dosing guidance for humans. Here is what the findings suggest, and what they do not.
This page is available in